MA38472B1 - Composé peptidique - Google Patents
Composé peptidiqueInfo
- Publication number
- MA38472B1 MA38472B1 MA38472A MA38472A MA38472B1 MA 38472 B1 MA38472 B1 MA 38472B1 MA 38472 A MA38472 A MA 38472A MA 38472 A MA38472 A MA 38472A MA 38472 B1 MA38472 B1 MA 38472B1
- Authority
- MA
- Morocco
- Prior art keywords
- peptide compound
- relates
- medicament
- receptors
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un nouveau composé peptidique ayant pour effet d'activer les récepteurs au glp-1 et les récepteurs au gip, ainsi que l'utilisation dudit composé peptidique en tant que médicament. L'invention concerne, plus précisément, un peptide contenant une séquence partielle représentée par la formule (i), ou un sel de celui-ci et un médicament en contenant. P
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013111893 | 2013-05-28 | ||
PCT/JP2014/002772 WO2014192284A1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38472A1 MA38472A1 (fr) | 2018-01-31 |
MA38472B1 true MA38472B1 (fr) | 2018-09-28 |
Family
ID=50942304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38472A MA38472B1 (fr) | 2013-05-28 | 2014-05-27 | Composé peptidique |
Country Status (36)
Country | Link |
---|---|
US (2) | US10087229B2 (fr) |
EP (1) | EP3004155B1 (fr) |
JP (2) | JP6429799B2 (fr) |
KR (1) | KR102229051B1 (fr) |
CN (1) | CN105209485B (fr) |
AP (1) | AP2015008781A0 (fr) |
AR (1) | AR096440A1 (fr) |
AU (1) | AU2014272500B2 (fr) |
CA (1) | CA2908581C (fr) |
CL (1) | CL2015003031A1 (fr) |
CY (1) | CY1124790T1 (fr) |
DK (1) | DK3004155T3 (fr) |
DO (1) | DOP2015000261A (fr) |
EA (2) | EA202090593A3 (fr) |
EC (1) | ECSP15044389A (fr) |
ES (1) | ES2900744T3 (fr) |
GE (1) | GEP201706762B (fr) |
HK (1) | HK1216757A1 (fr) |
HR (1) | HRP20212014T1 (fr) |
HU (1) | HUE057361T2 (fr) |
IL (1) | IL242005B (fr) |
LT (1) | LT3004155T (fr) |
MA (1) | MA38472B1 (fr) |
MX (2) | MX2015015464A (fr) |
MY (1) | MY172744A (fr) |
PE (1) | PE20151770A1 (fr) |
PH (1) | PH12015502391A1 (fr) |
PL (1) | PL3004155T3 (fr) |
PT (1) | PT3004155T (fr) |
SG (1) | SG11201507934PA (fr) |
SI (1) | SI3004155T1 (fr) |
TN (1) | TN2015000451A1 (fr) |
TW (1) | TWI638831B (fr) |
UA (1) | UA118558C2 (fr) |
UY (1) | UY35589A (fr) |
WO (1) | WO2014192284A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014272500B2 (en) | 2013-05-28 | 2018-03-08 | Scohia Pharma, Inc. | Peptide compound |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
CN104846061A (zh) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | 一种glp-1受体激动剂的受体亲和力测定方法 |
CN105388239B (zh) * | 2015-12-18 | 2018-01-05 | 兆科药业(合肥)有限公司 | 一种多肽固相合成的监测方法 |
WO2017204219A1 (fr) * | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | Composé peptidique |
WO2018104263A1 (fr) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin |
JOP20180028A1 (ar) * | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019140030A1 (fr) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
BR112020014596A2 (pt) * | 2018-01-23 | 2020-12-08 | Gila Therapeutics, Inc. | Formulações, composições e métodos farmacêuticos de peptídeo yy |
EP3788063B1 (fr) * | 2018-05-04 | 2023-08-09 | Novo Nordisk A/S | Dérivés de gip et leurs utilisations |
CN110818771B (zh) * | 2018-08-14 | 2023-01-17 | 陈铭 | 使用氨基酸离子液体的羰基硫介导多肽合成 |
JP7511548B2 (ja) * | 2018-09-24 | 2024-07-05 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
WO2020067557A2 (fr) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur du gip et leurs utilisations |
US20220411461A1 (en) * | 2019-08-19 | 2022-12-29 | Eli Lilly And Company | Methods of making incretin analogs |
CN114786706A (zh) | 2019-10-04 | 2022-07-22 | 韩美药品株式会社 | 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途 |
CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
KR20230005184A (ko) * | 2020-03-25 | 2023-01-09 | 다케다 야쿠힌 고교 가부시키가이샤 | Gip 수용체 작용제 펩티드 화합물의 qd 투약 및 이의 용도 |
KR20230029480A (ko) | 2020-07-22 | 2023-03-03 | 노보 노르디스크 에이/에스 | 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 |
BR112023000229A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
CA3222051A1 (fr) | 2021-06-01 | 2022-12-08 | Nanjing Zhihe Medicine Technology Co., Ltd. | Derive polypeptidique ayant un effet d'activation a double cible de glp-1r et de gipr, procede de preparation associe et son utilisation |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2024012472A1 (fr) * | 2022-07-13 | 2024-01-18 | 杭州中美华东制药有限公司 | Agoniste double de glp-1/gip, son procédé de préparation et son utilisation |
WO2024059674A1 (fr) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Composés agonistes doubles de gip et de glp-1 |
WO2024141760A1 (fr) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions et procédés pour augmenter la biodisponibilité systémique d'un agent thérapeutique polypeptidique subissant une administration orale |
WO2024165571A2 (fr) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
DE69732572T2 (de) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | Verwendung von glp-1 peptiden |
AU3087599A (en) | 1998-03-19 | 1999-10-11 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1306091A3 (fr) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation de la prolifération des cellules de beta |
DK1137666T5 (da) * | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
CA2417590C (fr) | 2000-05-16 | 2009-08-11 | Sanwa Kagaku Kenkyusho Co., Ltd | Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite |
ATE432289T1 (de) | 2002-07-04 | 2009-06-15 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
WO2005058955A1 (fr) | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues du glp-1 |
WO2006049681A2 (fr) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Agonistes recepteur y2 neuropeptidiques selectifs |
SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
WO2006136374A2 (fr) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline |
CA2657578A1 (fr) | 2006-07-11 | 2008-01-17 | Harkness Pharmaceuticals, Inc. | Procedes de traitement de l'obesite en utilisant des facteurs de satiete |
JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
CL2007002634A1 (es) | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
WO2009067268A1 (fr) | 2007-11-23 | 2009-05-28 | Michael Rothkopf | Procédés d'amplification de la résolution d'un diabète |
CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
CN102171243A (zh) * | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物 |
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
IN2012DN00377A (fr) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
EP2450374B9 (fr) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide et son utilisation |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
BR112013015861A2 (pt) | 2010-12-22 | 2018-06-05 | Marcadia Biotech Inc | métodos para reduzir ganho de peso ou induzir perda de peso, e para tratar hiperglicemia, reduzir níveis de glicose no sangue, ou normalizar níveis de glicose no sangue. |
EP2694095B1 (fr) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation |
AU2012266269B2 (en) | 2011-06-10 | 2017-04-06 | Novo Nordisk A/S | Polypeptides |
WO2012167744A1 (fr) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
US9758560B2 (en) | 2011-09-06 | 2017-09-12 | Novo Nordisk A/S | GLP-1 derivatives |
CA2862516C (fr) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions et methodes d'utilisation pour le traitement de troubles metaboliques |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
CN104519902B (zh) | 2012-05-08 | 2017-10-27 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
WO2013192310A1 (fr) | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Production à grande échelle et contrôle de dimension de nanoparticules par l'intermédiaire de microvortex régulés |
TWI644920B (zh) | 2012-06-21 | 2018-12-21 | 美商印第安納大學科技研究公司 | 展現gip受體活性之胰高血糖素類似物 |
TWI599575B (zh) | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現gip受體活性之胰高血糖素類似物 |
EP2935318A1 (fr) | 2012-12-19 | 2015-10-28 | Novo Nordisk A/S | Nouveaux agonistes des récepteurs à la glp-1 avec activité d'efflux du cholestérol |
AR094180A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Derivados de exendina-4 |
AU2014230472A1 (en) | 2013-03-14 | 2015-10-01 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
AU2014272500B2 (en) | 2013-05-28 | 2018-03-08 | Scohia Pharma, Inc. | Peptide compound |
WO2015067716A1 (fr) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Composés agonistes triples glucagon-glp-1-gip |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2014
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/hu unknown
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/hr unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/fr active Active
- 2014-05-27 UA UAA201510946A patent/UA118558C2/uk unknown
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 ES ES14729976T patent/ES2900744T3/es active Active
- 2014-05-27 PL PL14729976T patent/PL3004155T3/pl unknown
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/lt unknown
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/xx unknown
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/da active
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/fr active Application Filing
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/es unknown
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 AR ARP140102090A patent/AR096440A1/es unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/zh active
- 2014-05-27 MA MA38472A patent/MA38472B1/fr unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/ru unknown
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/ko active IP Right Grant
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/ja active Active
- 2014-05-27 MX MX2015015464A patent/MX2015015464A/es active IP Right Grant
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/fr active Active
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/zh active Active
- 2014-05-27 UY UY0001035589A patent/UY35589A/es not_active Application Discontinuation
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 EA EA201591891A patent/EA035813B1/ru unknown
- 2014-05-27 PT PT147299762T patent/PT3004155T/pt unknown
- 2014-05-27 SI SI201431933T patent/SI3004155T1/sl unknown
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/es unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391A1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/es unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/es unknown
- 2015-11-06 MX MX2019010531A patent/MX2019010531A/es unknown
-
2016
- 2016-04-28 HK HK16104856.7A patent/HK1216757A1/zh unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/ja active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38472B1 (fr) | Composé peptidique | |
MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
BR112017006253A2 (pt) | novos compostos | |
MA39246A1 (fr) | Composé hétérocyclique fusionné | |
EA201501142A1 (ru) | Гетероциклические соединения в качестве средств для борьбы с вредителями | |
EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
AR095523A1 (es) | Derivados piridin-4-ilo | |
MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
AR095097A1 (es) | Compuestos de fenoxietoxi | |
AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc | |
EA201692270A1 (ru) | Производные нафтиридиндиона | |
EA201591649A1 (ru) | Составы с органическими соединениями | |
MA39305A3 (fr) | Dérivés d'éthynyle | |
SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
AR099767A1 (es) | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
ES2571452T3 (es) | Compuesto antagonista de leucotrieno B4 | |
MA39108A1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie sévère | |
CL2018002422A1 (es) | Preparación que contiene agua de mar a la que se ha agregado un compuesto de potasio. | |
MX2015007568A (es) | Compuestos de malononitrilo para controlar plagas de animales. | |
DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir |